NCT03869762 2026-04-13
DICE
Cancer Trials Ireland
Phase 2 Terminated
Clinical Trials
16 trialsNCT01885949 2026-02-24
Tivozanib + Enzalutamide in Adv Prostate Cancer
Massachusetts General Hospital
Phase 2 Terminated
NCT05551117 2026-02-09
Tamarack
MacroGenics
Phase 2 Terminated
NCT05588609 2025-09-18
Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers
Merus B.V.
Phase 2 Terminated
NCT03770455 2024-07-09
Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC
Tulane University
Phase 2 Terminated
NCT03999515 2023-09-28
Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer
University of Washington
Phase 2 Terminated
NCT04157088 2023-08-04
DaroAcT
Bayer
Phase 2 Terminated
NCT02640534 2023-06-27
Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone
Swiss Cancer Institute
Phase 2 Terminated
NCT04142060 2022-10-28
ARIANNA
SOLTI Breast Cancer Research Group
Phase 2 Terminated
NCT03531827 2022-07-12
Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02508636 2021-10-12
Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer
University of California, San Francisco
Phase 2 Terminated
NCT02489123 2021-08-10
Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
University of Washington
Phase 2 Terminated
NCT02685267 2021-04-09
Doce/Enza
Prostate Cancer Clinical Trials Consortium
Phase 2 Terminated
NCT02758132 2019-11-08
Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases
University of Hawaii
Phase 2 Terminated
NCT02379390 2019-06-21
PRIMCAB
Sanofi
Phase 2 Terminated
NCT02605863 2018-10-03
Enzalutamide for Bladder Cancer Chemoprevention
University of Rochester
Phase 2 Terminated